CAS: 2315-97-1; 9,9'-Biacridinium, 10,10'-Dimethyl-, Nitrate (1:2)

专利信息

专利号:US-2007088086-A1
优先权日:1999-08-16
标题 :Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis
发明人：SPALLHOLZ JULIAN E; REID TED W; WALKUP ROBERT D
权利人:PHARMASE INC
摘要:A synthesis of and use for L-Se-methylselenocysteine as a nutriceutical is described, based upon the knowledge that L-Se-methylselenocysteine is less toxic than L-selenomethionine towards normal cells. The synthesis proceeds by mixing N-(tert-butoxycarbonyl)-L-serine with a dialkyl diazodicarboxylate and at least one of a trialkylphosphine, triarylphosphine, and phosphite to form a first mixture that includes N-(tert-butoxycarbonyl)-L-serine β-lactone. Methyl selenol or its salt is mixed with the N-(tert-butoxycarbonyl)-L-serine β-lactone to form a second mixture that includes N-(tert-butoxycarbonyl)-Se-methylselenocysteine. The tert-butoxycarbonyl group is removed from the N-(tert-butoxycarbonyl)-Se-methylselenocysteine to form L-Se-methylselenocysteine. This synthesis significantly improves the manufacturability, manufacturing efficiency, and utility of this naturally occurring rare form of organic-selenium. L-Se-methylselenocysteine formed, for example, in this manner may be used as a nutriceutical for supplementation into the diets of humans or animals for various beneficial purposes, such as, for example, to prevent or reduce the risk of developing cancer.

专利号:US-2002022022-A1
优先权日:2000-05-19
标题 :Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors
发明人：SHI YI; ZALEWSKI ANDREW
摘要:The present invention is directed to a method for the prophylactic and therapeutic treatment of diseases or disorders associated with the abnormal proliferation and extracellular matrix synthesis of smooth muscle cells (SMC) and fibroblasts due to activation of NAD(P)H and/or increased ROS generation. The method involves the administration of an NAD(P)H oxidase inhibitor(s) and/or antioxidant(s) to a mammal in an amount sufficient to treat the disease or disorder prophylactically or therapeutically. The NAD(P)H oxidase inhibitor inhibits the synthesis or translocation of NAD(P)H subunits, thereby blocking the generation of intracellular reactive oxygen species (ROS) and thus the proliferation and extracellular matrix synthesis of SMC and fibroblasts. Similarly, the administration of antioxidants blocks the generation of intracellular ROS, thereby inhibiting SMC and fibroblast proliferation and extracellular matrix synthesis. In addition to the prevention and treatment of vascular disease, such as atherosclerosis, graft disease, and restenosis, NAD(P)H oxidase inhibitors and antioxidants may be useful for the prevention and treatment of other conditions by decreasing cell proliferation and extracellular matrix synthesis associated therewith. These conditions include arthritis, keloid formation, cancer, tissue and organ fibrosis, and complications related to organ transplantation, metabolic syndrome, and radiation therapy.

专利号:EP-1205471-A1
优先权日:2000-10-02
标题:A method of using synthetic L-SE-Methylselenocysteine as a nutriceutical and a method of its synthesis
发明人：SPALLHOLZ JULIAN E; REID TED W; WALKUP ROBERT D
权利人:PHARMASE INC
摘要:A synthesis of and use of L-Se-methylselenocysteine as a nutriceutical isndescribed, based upon the knowledge that L-Se-methylselenocysteine is lessntoxic than L-selenomethionine towards normal cells. The synthesis proceedsnby mixing N-(tert-butoxycarbonyl)-L-serine with a dialkyl diazodicarboxylatenand at least one of a trialkylphosphine, triarylphosphine and phosphite to formna first mixture that includes N-(tert-butoxycarbonyl)-L-serine β-lactone.nMethyl selenol or its salt is mixed with the N-(tert-butoxycarbonyl)-L-serine β-lactonento form a second mixture that includes N-(tert-butoxycarbonyl)-Se-methylselenocysteine.nThe text butoxycarbonyl group is removed from the N-(tert-butoxycarbonyl)-Se-methylselenocysteinento form L-Se-methylselenocysteine.nThis synthesis significantly improves thenmanufacturability, manufacturing efficiency and utility of this naturallynoccurring rare form of organic-selenium. L-Se-methylselenocysteine formed,nfor example, in this manner may be used as a nutriceutical for supplementationninto the diets of humans or animals for various beneficial purposes, such as, fornexample, to prevent or reduce the risk of developing cancer.

专利号:US-2005080260-A1
优先权日:2003-04-22
标 题 :Preparation of prodrugs for selective drug delivery
发明人：MILLS RANDELL L; WU GUO-ZHANG
摘要:Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

专利号:US-5866335-A
优先权日:1994-06-24
标题:Preparation of derivatized 10,10'-substituted-9,9'-biacridine luminescent molecules and signal solutions
发明人：KATSILOMETES GEORGE W; HO PAK T
权利人:KATSILOMETES GEORGE W
摘要:The synthesis of 10,10'-substituted-9,9'-biacridine molecules and their derivatives is disclosed. These molecules are shown to catalyze the production of light by chemiluminescence in the presence of a signal solution having at a pH from about 10.0 to about 14.0, at a concentration effective for producing a chemiluminescent signal, a chelating agent, a sulfoxide, a reducing sugar, an oxidant or combination of oxidants, an alcohol and aqueous sodium tetraborate. These 10,10'-substituted-9,9'-biacridines are used alone or attached to haptens or macromolecules and are utilized as labels in the preparation of chemiluminescent, homogeneous or heterogeneous assays. They are also used in conjunction with other chemiluminescent label molecules to produce multiple analyte chemiluminescent assays.

专利号:US-9629855-B2
优先权日:2011-12-29
标 题 :Pharmaceutical composition for treatment of eye pain, containing PGE2 synthesis inhibitor
发明人：LEE HYUNG KEUN; SHIM JONG WOO
权利人:INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIV
摘要:The present invention relates to a pharmaceutical composition for the treatment of eye pain, containing a PGE2 synthesis inhibitor. The use of the pharmaceutical composition for the prevention or treatment of eye pain according to the present invention, which contains the PGE2 synthesis inhibitor as an active ingredient, makes it possible to alleviate the symptoms of eye pain by selectively inhibiting the PGE2 expression level, and also has the advantages of treating and preventing xerophthalmia and of overcoming and preventing eye discomfort caused by various inflammation-inducing circumstances including following surgery. Also, by using a kit for detecting the amount of PGE2, PGD2 and COX2, the present invention makes it possible to easily diagnose eye-pain symptoms in clinical practice, and can be widely used in checking the state not only of patients having xerophthalmia but also patients following eye surgery.